Pancreatic Cancer Research

ResearcherUniversity of Naples Federico IIActive in the last 2 years

Roberto Bianco

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3311-260X; OpenAlex author ID A5040413764. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 8

  1. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  2. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  3. FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Last author DOI 10.2217/fon-2021-1142↗
  4. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomi… Co-author DOI 10.1016/j.ejca.2021.02.023↗
  5. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  6. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. Last author DOI 10.3390/cancers13194939↗
  7. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Last author DOI 10.1177/1758835920947970↗
  8. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Lite… Last author DOI 10.3390/cancers11070981↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alberto Zaniboni · 3 shared papers, 2021–2026 · strength 0.44
  2. Enrico Vasile · 3 shared papers, 2020–2026 · strength 0.43
  3. Francesca Foschini · 4 shared papers, 2019–2022 · strength 0.42
  4. Fabiana Napolitano · 4 shared papers, 2019–2022 · strength 0.42
  5. Priscilla Cascetta · 4 shared papers, 2019–2022 · strength 0.42
  6. Alberto Servetto · 4 shared papers, 2019–2022 · strength 0.42
  7. Letizia Procaccio · 2 shared papers, 2024–2026 · strength 0.35
  8. Elisa Giommoni · 2 shared papers, 2024–2026 · strength 0.35
  9. Sara Lonardi · 2 shared papers, 2024–2026 · strength 0.35
  10. Ferdinando De Vita · 2 shared papers, 2024–2026 · strength 0.35
  11. Francesca Bergamo · 2 shared papers, 2024–2026 · strength 0.35
  12. Guido Giordano · 2 shared papers, 2024–2026 · strength 0.35
  13. Matteo Landriscina · 2 shared papers, 2024–2026 · strength 0.35
  14. Giampaolo Tortora · 2 shared papers, 2024–2026 · strength 0.35
  15. Davide Melisi · 2 shared papers, 2024–2026 · strength 0.35
  16. Caterina Vivaldi · 2 shared papers, 2020–2026 · strength 0.28
  17. Michèle Milella · 2 shared papers, 2021–2024 · strength 0.25
  18. Chiara Carmen Miceli · 1 shared paper, 2026 · strength 0.20
  19. Mario Scartozzi · 1 shared paper, 2026 · strength 0.20
  20. Federico Nichetti · 1 shared paper, 2026 · strength 0.20
  21. Andrea Pretta · 1 shared paper, 2026 · strength 0.20
  22. Simona Casalino · 1 shared paper, 2026 · strength 0.20
  23. Mariacristina Di Marco · 1 shared paper, 2026 · strength 0.20
  24. Giuseppe Aprile · 1 shared paper, 2026 · strength 0.20
  25. Monica Niger · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.